Parametric Portfolio Associates LLC raised its position in shares of Celgene Co. (NASDAQ:CELG) by 7.9% in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,236,649 shares of the biopharmaceutical company’s stock after purchasing an additional 163,486 shares during the quarter. Parametric Portfolio Associates LLC owned about 0.32% of Celgene worth $206,756,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also made changes to their positions in the company. Archford Capital Strategies LLC grew its position in Celgene by 277.8% during the 1st quarter. Archford Capital Strategies LLC now owns 272 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 200 shares in the last quarter. Liberty Wealth Management LLC lifted its position in shares of Celgene by 212.8% in the second quarter. Liberty Wealth Management LLC now owns 294 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 200 shares in the last quarter. Weaver Consulting Group purchased a new stake in shares of Celgene in the first quarter worth approximately $29,000. Alera Investment Advisors LLC boosted its holdings in shares of Celgene by 109.9% during the first quarter. Alera Investment Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 167 shares during the period. Finally, Mizuho Securities Co. Ltd. acquired a new stake in shares of Celgene during the first quarter worth approximately $31,000. 72.51% of the stock is currently owned by institutional investors.
Several research analysts have weighed in on CELG shares. ValuEngine lowered shares of Celgene from a “sell” rating to a “strong sell” rating in a research note on Thursday, August 1st. Mizuho lowered Celgene from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $103.00 to $100.00 in a research report on Monday, August 19th. BidaskClub lowered Celgene from a “buy” rating to a “hold” rating in a research report on Saturday. Cowen reaffirmed a “hold” rating and set a $102.00 price target on shares of Celgene in a research note on Tuesday, July 30th. Finally, Zacks Investment Research upgraded Celgene from a “sell” rating to a “hold” rating and set a $94.00 price target for the company in a report on Tuesday, July 23rd. One analyst has rated the stock with a sell rating, eighteen have assigned a hold rating and three have issued a buy rating to the company’s stock. Celgene presently has a consensus rating of “Hold” and an average price target of $94.60.
Celgene (NASDAQ:CELG) last announced its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $2.61 EPS for the quarter, beating the consensus estimate of $2.44 by $0.17. Celgene had a return on equity of 89.93% and a net margin of 32.24%. The company had revenue of $4.40 billion for the quarter, compared to the consensus estimate of $4.22 billion. During the same quarter last year, the company posted $2.16 earnings per share. The company’s revenue for the quarter was up 15.4% compared to the same quarter last year. On average, sell-side analysts forecast that Celgene Co. will post 9.96 EPS for the current year.
Celgene Company Profile
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.